Oppenheimer analyst Francois Brisebois maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research Report) today and set a price target of $4.00. The company’s shares closed yesterday at $0.84.
According to TipRanks, Brisebois is an analyst with an average return of -4.9% and a 32.88% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Cybin, Tarsus Pharmaceuticals, and Avadel Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sensei Biotherapeutics with a $4.67 average price target, representing a 455.95% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $4.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $1.93 and a one-year low of $0.51. Currently, Sensei Biotherapeutics has an average volume of 52.64K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensei Biotherapeutics (SNSE) Company Description:
Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The companies ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.
Read More on SNSE:
- Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Sensei Biotherapeutics reports FY23 EPS ($1.22), consensus ($1.22)
- Sensei Biotherapeutics Streamlines Board, Appoints Interim Chair
- Sensei Biotherapeutics Announces Board Member Resignation and Consultant Role
- Sensei Biotherapeutics to Present at Upcoming Conferences
